Table 4.
Prospective and retrospective trials evaluating consolidative radiation therapy for ED SCLC
| Study | Type | Patient Selection | Treatment | Med Survival | 1 year OS | 2yr OS | 5 yr OS | |
|---|---|---|---|---|---|---|---|---|
| RTOG 0937 | PhIIr (n=86) |
1–4 metastatic lesions RT after ChT response | ChT–>RT 45 Gy at 3Gy/fx | 13.8 mos | 50.8% | NA | NA | NS |
| ChT | 15.8 mos | 60.1% | ||||||
|
| ||||||||
| Jeremic 1999 | PhIIIr (n=109) |
All Patients with EDSLC with CR to DM with 3 cycles of ChT | ChT–>Cht/RT 54 Gy at 1.5Gy/fx |
17mos | 65% | 38% | 9.1% | p=0.041 |
| ChT | 11 mos | 46% | 28% | 3.7% | ||||
|
| ||||||||
| CREST 2015 | Phase IIIr (n=495) |
All patients with EDSCLC with ChT Response | ChT–>RT 30 Gy at 3Gy/fx |
11.8 mos | 33% | 13% | NA | p<0.0001 |
| ChT | 7.5 mos | 28% (NS) | 3% | |||||
|
| ||||||||
| Zhu 2011 | Single institution Retrospective (n-119) |
Variable | ChT/RT 40–60 Gy 1.8–2Gy/Fx |
17 mos | NA | 35% | 7.1% | p=0.014 |
| ChT | 19.3 mos | 17% | 5.1% | |||||
|
| ||||||||
| Ou 2009 | Regional Database (n=4782) |
Variable | ChT/RT | 8 mos | 27.8% | 9.3% | NA | p<0.0001 |
| ChT | 4 mos | 16.2% | 3.8% | |||||